Castro E Silva Juliana Helena, Pieropan Francesca, Rivera Andrea Domenico, Butt Arthur Morgan, Costa Silvia Lima
Laboratory of Neurochemistry and Cellular Biology, Department of Biofunction, Health Sciences Institute, Federal University of Bahia, Salvador 40231-300, Brazil.
School of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2UP, UK.
Nutrients. 2024 Nov 26;16(23):4053. doi: 10.3390/nu16234053.
Reactive astrogliosis and microgliosis are coordinated responses to CNS insults and are pathological hallmarks of traumatic brain injury (TBI). In these conditions, persistent reactive gliosis can impede tissue repopulation and limit neurogenesis. Thus, modulating this phenomenon has been increasingly recognized as potential therapeutic approach.
In this study, we investigated the potential of the flavonoid agathisflavone to modulate astroglial and microglial injury responses and promote neurogenesis in the subventricular zone (SVZ) neurogenic niche. Agathisflavone, or the vehicle in controls, was administered directly into the lateral ventricles in postnatal day (P)8-10 mice by twice daily intracerebroventricular (ICV) injections for 3 days, and brains were examined at P11.
In the controls, ICV injection caused glial reactivity along the needle track, characterised immunohistochemically by increased astrocyte expression of glial fibrillary protein (GFAP) and the number of Iba-1+ microglia at the lesion site. Treatment with agathisflavone decreased GFAP expression, reduced both astrocyte reactivity and the number of Iba-1 microglia at the core of the lesion site and the penumbra, and induced a 2-fold increase on the ratio of anti-inflammatory CD206+ to pro-inflammatory CD16/32+ microglia. Notably, agathisflavone increased the population of neuroblasts (GFAP+ type B cells) in all SVZ microdomains by up to double, without significantly increasing the number of neuronal progenitors (DCX+).
Although future studies should investigate the underlying molecular mechanisms driving agathisflavone effects on microglial polarization and neurogenesis at different timepoints, these data indicate that agathisflavone could be a potential adjuvant treatment for TBI or central nervous system disorders that have reactive gliosis as a common feature.
反应性星形胶质细胞增生和小胶质细胞增生是对中枢神经系统损伤的协同反应,是创伤性脑损伤(TBI)的病理标志。在这些情况下,持续的反应性胶质细胞增生会阻碍组织再生并限制神经发生。因此,调节这一现象已越来越被视为一种潜在的治疗方法。
在本研究中,我们研究了黄酮类化合物贝壳杉黄酮调节星形胶质细胞和小胶质细胞损伤反应以及促进脑室下区(SVZ)神经生发微环境中神经发生的潜力。在出生后第(P)8 - 10天的小鼠中,通过每天两次脑室内(ICV)注射,持续3天,将贝壳杉黄酮或对照组中的赋形剂直接注入侧脑室,并在P11时检查大脑。
在对照组中,脑室内注射导致沿针道的胶质细胞反应,免疫组织化学特征为损伤部位胶质纤维酸性蛋白(GFAP)的星形胶质细胞表达增加以及Iba - 1 +小胶质细胞数量增加。用贝壳杉黄酮治疗可降低GFAP表达,减少损伤部位核心和半暗带处的星形胶质细胞反应性以及Iba - 1小胶质细胞数量,并使抗炎性CD206 +与促炎性CD16/32 +小胶质细胞的比例增加2倍。值得注意的是,贝壳杉黄酮使所有SVZ微区中的神经母细胞(GFAP + B型细胞)数量增加多达一倍,而不会显著增加神经元祖细胞(DCX +)的数量。
尽管未来的研究应探究驱动贝壳杉黄酮在不同时间点对小胶质细胞极化和神经发生产生影响的潜在分子机制,但这些数据表明贝壳杉黄酮可能是TBI或具有反应性胶质细胞增生这一共同特征的中枢神经系统疾病的潜在辅助治疗药物。